Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Pheast Therapeutics
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
Eastern Cooperative Oncology Group
Avera McKennan Hospital & University Health Center